Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines? (Q54509553)

From Wikidata

Jump to navigation Jump to search

scientific article

edit

Language	Label	Description	Also known as
English	Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines?	scientific article

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

22614986

retrieved

30 May 2018

reference URL

http://europepmc.org/abstract/MED/22614986

title

Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines? (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

22614986

retrieved

30 May 2018

reference URL

http://europepmc.org/abstract/MED/22614986

main subject

chemotherapy

1 reference

based on heuristic

inferred from title

author

Larry Norton

series ordinal

7

1 reference

stated in

Europe PubMed Central

PubMed publication ID

22614986

retrieved

30 May 2018

reference URL

http://europepmc.org/abstract/MED/22614986

Gabriel N Hortobagyi

series ordinal

4

object named as

Gabriel N Hortobagyi

1 reference

stated in

Europe PubMed Central

PubMed publication ID

22614986

retrieved

30 May 2018

reference URL

http://europepmc.org/abstract/MED/22614986

Edith A. Perez

series ordinal

3

object named as

Edith A Perez

1 reference

stated in

Europe PubMed Central

PubMed publication ID

22614986

retrieved

30 May 2018

reference URL

http://europepmc.org/abstract/MED/22614986

Clifford A Hudis

series ordinal

9

object named as

Clifford A Hudis

1 reference

stated in

Europe PubMed Central

PubMed publication ID

22614986

retrieved

30 May 2018

reference URL

http://europepmc.org/abstract/MED/22614986

Eric Winer

series ordinal

8

object named as

Eric P Winer

1 reference

stated in

Europe PubMed Central

PubMed publication ID

22614986

retrieved

30 May 2018

reference URL

http://europepmc.org/abstract/MED/22614986

Martine Piccart-Gebhart

series ordinal

2

object named as

Martine J Piccart-Gebhart

1 reference

stated in

Europe PubMed Central

PubMed publication ID

22614986

retrieved

30 May 2018

reference URL

http://europepmc.org/abstract/MED/22614986

Norman Wolmark

series ordinal

5

object named as

Norman Wolmark

1 reference

stated in

Europe PubMed Central

PubMed publication ID

22614986

retrieved

30 May 2018

reference URL

http://europepmc.org/abstract/MED/22614986

Kathy S. Albain

series ordinal

6

object named as

Kathy S Albain

1 reference

stated in

Europe PubMed Central

PubMed publication ID

22614986

retrieved

30 May 2018

reference URL

http://europepmc.org/abstract/MED/22614986

author name string

Harold J Burstein

series ordinal

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

22614986

retrieved

30 May 2018

reference URL

http://europepmc.org/abstract/MED/22614986

language of work or name

English

0 references

publication date

21 May 2012

1 reference

stated in

Europe PubMed Central

PubMed publication ID

22614986

retrieved

30 May 2018

reference URL

http://europepmc.org/abstract/MED/22614986

published in

Journal of Clinical Oncology

1 reference

stated in

Europe PubMed Central

PubMed publication ID

22614986

retrieved

30 May 2018

reference URL

http://europepmc.org/abstract/MED/22614986

volume

30

1 reference

stated in

Europe PubMed Central

PubMed publication ID

22614986

retrieved

30 May 2018

reference URL

http://europepmc.org/abstract/MED/22614986

issue

18

1 reference

stated in

Europe PubMed Central

PubMed publication ID

22614986

retrieved

30 May 2018

reference URL

http://europepmc.org/abstract/MED/22614986

page(s)

2179-2182

1 reference

stated in

Europe PubMed Central

PubMed publication ID

22614986

retrieved

30 May 2018

reference URL

http://europepmc.org/abstract/MED/22614986

cites work

Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6076002

retrieved

7 September 2018

Adjuvant trastuzumab in HER2-positive breast cancer

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6076002

retrieved

7 September 2018

Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6076002

retrieved

7 September 2018

Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6076002

retrieved

7 September 2018

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6076002

retrieved

7 September 2018

Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6076002

retrieved

7 September 2018

Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active th

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6076002

retrieved

7 September 2018

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6076002

retrieved

7 September 2018

Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6076002

retrieved

7 September 2018

Role of anthracyclines in the treatment of early breast cancer

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6076002

retrieved

7 September 2018

Weekly paclitaxel in the adjuvant treatment of breast cancer.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6076002

retrieved

7 September 2018

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6076002

retrieved

7 September 2018

Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6076002

retrieved

7 September 2018

Troponin I and C-Reactive Protein Are Commonly Detected in Patients with Breast Cancer Treated with Dose-Dense Chemotherapy Incorporating Trastuzumab and Lapatinib

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6076002

retrieved

30 November 2018

HER2 and Response to Paclitaxel in Node-Positive Breast Cancer

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6076002

retrieved

30 November 2018

Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=6076002

retrieved

30 November 2018

HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/22614986

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Bre

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/22614986

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

DOI

10.1200/JCO.2012.42.0695

1 reference

stated in

Europe PubMed Central

PubMed publication ID

22614986

retrieved

30 May 2018

reference URL

http://europepmc.org/abstract/MED/22614986

Fatcat ID

release_xjkoowz2rzewncia2t7j4ncaue

1 reference

stated in

Fatcat

reference URL

https://api.fatcat.wiki/v0/release/xjkoowz2rzewncia2t7j4ncaue

retrieved

24 November 2022

based on heuristic

mapped directly with Wikidata item

PMC publication ID

6076002

0 references

PubMed publication ID

22614986

1 reference

stated in

Europe PubMed Central

PubMed publication ID

22614986

retrieved

30 May 2018

reference URL

http://europepmc.org/abstract/MED/22614986

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54509553&oldid=1872228245"